Cardiff Oncology Inc logo

Cardiff Oncology Inc(CRDF)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.85
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CRDF

11/20/2026: CRDF (1-star) is currently NOT-A-BUY. Pass it for now.

Cardiff Oncology Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies, most notably its lead product candidate onvansertib for hard-to-treat solid tumors. The company's primary strength lies in encouraging early-stage Phase 2 clinical data demonstrating improved response rates when combining onvansertib with standard-of-care treatments for metastatic colorectal cancer. Its main investment story centers on advancing this asset into registrational Phase 3 trials to address significant unmet medical needs. However, the company faces substantial execution, financial, and clinical risks typical of pre-revenue biotechnology firms dependent on external funding. This stock is best suited for growth-oriented investors with high risk tolerance who are willing to monitor upcoming clinical trial readouts and capital-raising updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers high-growth optionality tied to the clinical advancement of its lead oncology drug candidate.
Momentum investorStrong fit while signal remains positiveStock price behavior is heavily driven by clinical trial catalysts and positive data readouts.
Value investorWeak fitAs a pre-profit clinical-stage biotech with minimal commercial revenue, traditional valuation metrics do not apply.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for clinical development.
Low-risk investorWeak fitHigh clinical, regulatory, and capital-raising risks create substantial share price volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience sharp price movements around data disclosures and capital needs.
Valuation riskMedium / highValuations are driven by speculative clinical potential rather than trailing earnings or cash flows.
Competition risk (targeted oncology competitors)HighAlternative treatments developed by competing biotech firms could surpass or diminish the market opportunity for onvansertib.
Business qualityMediumThe company possesses promising scientific assets but lacks commercial-stage commercial scale and infrastructure.
Dividend incomeLow / noneNo cash dividends are distributed to shareholders.
Execution riskHighSuccessful clinical trial execution and regulatory approval processes are vital for corporate survival and value creation.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 69.44M USD
Price to earnings Ratio -
1Y Target Price 5.14
Price to earnings Ratio -
1Y Target Price 5.14
Volume (30-day avg) 1.3M shares
Beta 1.56
52 Weeks Range 0.71 - 3.31
Updated Date 11/20/2026
52 Weeks Range 0.71 - 3.31
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.54

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 21.91%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CRDF receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
CRDF has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: slightly negative earnings growth (-0.9%), weak cash generation (FCF margin -6402.5%), negative revenue growth (-13.2%).

Financial Health Rating

★★★★★
CRDF's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 70.7%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
CRDF's growth profile is soft, with the least-weak measure being free-cash-flow growth at -0.5% FY2025 versus FY2024. By comparison, while revenue growth (-13.2%, negative) and earnings growth (-0.9%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 20.5% and approximately 96.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.20% supports management-shareholder alignment.

Top 5 Institutional Investors

LAURION CAPITAL MANAGEMENT LP 3.98%
Vanguard Capital Management, LLC 3.72%
Pfizer Inc 3.10%
Franklin Templeton Inc 1.55%
BlackRock Inc 1.25%

Unit Economics (Per $1K Revenue)

★★★★★
CRDF generates approximately $1,000 of gross profit, $-82,563 of operating income, and $-64,025 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
CRDF has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Licensing and RoyaltiesEarly-stage royalty revenues generated from legacy agreements or collaborative intellectual property partnerships.Currently, the company generates negligible commercial revenue and operates primarily as a clinical-stage research entity.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 32.80M
Price to Sales(TTM) 136.69
Enterprise Value 32.80M
Price to Sales(TTM) 136.69
Enterprise Value to Revenue 58.68
Enterprise Value to EBITDA -3.66
Shares Outstanding 77.80M
Shares Floating 75.38M
Shares Outstanding 77.80M
Shares Floating 75.38M
Percent Insiders 6.2
Percent Institutions 20.53

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.